|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Notice to Readers Unavailability of Streptomycin and Para-Aminosalicylic Acid in the United StatesStreptomycin (SM) and para-aminosalicylic acid (PAS), antimicrobial agents used to treat tuberculosis (TB), are currently unavailable in the United States. Because of problems in the supply of bulk SM, which is produced outside the United States, the U.S. manufacturer has ceased production of the finished product. The U.S. manufacturer of PAS has voluntarily discontinued production on a temporary basis. Although CDC and the Food and Drug Administration are attempting to reestablish production of these drugs, health-care providers should be prepared for an interruption in their supply. For guidance in selecting appropriate alternatives to SM and PAS for the treatment of TB, health-care providers should contact their state or local TB control program. Disclaimer All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 08/05/98 |
|||||||||
This page last reviewed 5/2/01
|